After AstraZeneca, will the French be suspicious of the vaccine marketed by Pfizer? According to the National Medicines Safety Agency (ANSM), which publishes a monitoring point for vaccines against Covid-19 every week, five cases of myocarditis have been detected in France in people who had been vaccinated with Pfizer. Those data published on Friday April 30, 2021 do not bring, “at this stage, enough elements to conclude on a role of the vaccine, but nevertheless constitute a potential signal”, however insisted on the ANSM. The agency’s monitoring committee decided to re-analyze data related to myocarditis on French territory after receiving a report of cases in young men who had been administered this vaccine in Israel.
But for the time being, there is no questioning of the benefit / risk ratio, especially since this inflammation of the myocardium is benign in a large majority of cases. These side effects will still “subject to specific monitoring and will be shared at European level”, informed the ANSM.
Symptoms “expected and not serious”
Out of more than 13,660,000 injections carried out on April 22, 2021, only 16,030 cases of adverse side effects have been reported after vaccination with Pfizer. The vast majority of these are symptoms “expected and not serious” : pain where the product was injected or headaches, as pointed out The Parisian Friday, April 30, 2021. Transient increases in blood pressure and heart rhythm disturbances were also reported in February 2021. The French Society of Arterial Hypertension (SFHTA) had reassured the French in a communicated published on Sunday February 14, 2021: “Despite their benign and transient nature, these side effects have been widely reported by the media and could generate an illegitimate concern to the general public “, could we read there.
Read also : A dose of vaccine already halves the risk of infecting your home